e-learning
resources
ERJ
2011
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Effectiveness and safety of leflunomide for pulmonary and extrapulmonary sarcoidosis
Sahoo D.H., Bandyopadhyay D., Xu M., Pearson K., Parambil J.G., Lazar C.A., Chapman J.T., Culver D.A.
Source:
Eur Respir J 2011; 38: 1145-1150
Journal Issue:
November
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Sahoo D.H., Bandyopadhyay D., Xu M., Pearson K., Parambil J.G., Lazar C.A., Chapman J.T., Culver D.A.. Effectiveness and safety of leflunomide for pulmonary and extrapulmonary sarcoidosis. Eur Respir J 2011; 38: 1145-1150
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Pulmonary sarcoidosis
Definition and history of sarcoidosis
ERS clinical practice guidelines on treatment of sarcoidosis
Related content which might interest you:
Infliximab: An effective rescue therapy in refractory extra-pulmonary sarcoidosis
Source: Annual Congress 2013 –Sarcoidosis and other granulomatosis
Year: 2013
Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial
Source: Eur Respir J 2008; 31: 1189-1196
Year: 2008
The course of COVID-19 in pulmonary sarcoidosis patients, receiving methotrexate
Source: Virtual Congress 2021 – Moving forward in various aspects of sarcoidosis
Year: 2021
Azathioprine and low-dose prednisone in chronic pulmonary sarcoidosis
Source: Eur Respir J 2005; 26: Suppl. 49, 268s
Year: 2005
Methotrexate in the treatment of the chronic form of pulmonary and extra - pulmonary sarcoidosis
Source: Eur Respir J 2004; 24: Suppl. 48, 712s
Year: 2004
Sulphasalazine and lung toxicity
Source: Eur Respir J 2002; 19: 756-764
Year: 2002
Pentoxifylline in treatment of pulmonary sarcoidosis
Source: Eur Respir J 2002; 20: Suppl. 38, 433s
Year: 2002
Safety of corticosteroid therapy in patients with pulmonary sarcoidosis
Source: International Congress 2017 – The many faces of sarcoidosis
Year: 2017
Sarcoidosis
Source: Respipedia Article
Year: 2017
Severe lung involvement in systemic scleromyxoedema: a highly unusual finding
Source: Eur Respir J 2002; 19: 976-979
Year: 2002
The efficacy of treatment with surfactant-BL (S-BL) in patients with destructive pulmonary tuberculosis
Source: Annual Congress 2007 - Research perspectives: diagnosis and treatment of tuberculosis
Year: 2007
Response of pulmonary tuberculomas to anti-tuberculous treatment
Source: Eur Respir J 2004; 23: 452-455
Year: 2004
Standard therapy for sarcoidosis
Source: Annual Congress 2005 - Biological agents in the therapy of sarcoidosis
Year: 2005
Comparison of prednisolone and budesonide in the treatment of pulmonary sarcoidosis
Source: Eur Respir J 2005; 26: Suppl. 49, 80s
Year: 2005
Methotrexate as a single agent for the treatment of patients with progressive pulmonary sarcoidosis
Source: International Congress 2015 – Sarcoidosis: clinical
Year: 2015
Cyclophosphamide and low-dose prednisolone in idiopathic pulmonary fibrosis and fibrosing nonspecific interstitial pneumonia
Source: Eur Respir J 2005; 25: 528-533
Year: 2005
Does concomitant extrapulmonary involvement changes characteristic features of pulmonary sarcoidosis?
Source: Annual Congress 2013 –Sarcoidosis and other granulomatosis
Year: 2013
Iatrogenic adrenal insufficiency as a side-effect of combined treatment of itraconazole and budesonide
Source: Eur Respir J 2002; 20: 127-133
Year: 2002
Granulomatous angiitis leading to a pulmonary veno-occlusive disease-like picture
Source: Eur Respir J 2009; 33: 666-669
Year: 2009
Sarcoidosis, a systemic disease
Source: Annual Congress 2005 - Sarcoidosis: update on extrathoracic organ problems
Year: 2005
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept